¼¿ï¾Æ»êº´¿ø Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦35Â÷ KSTH Ãá°èÇмú´ëȸ : 2019-05-24±³À°ÀÏÀÚ : 2019-05-24
±³À°Àå¼Ò : ¼¿ï¾Æ»êº´¿ø ±³À°¿¬±¸°ü ÁöÇÏ1Ãþ ´ë°´ç, ¼Ò°´ç
±³À°ÁÖÁ¦ :
Á¦35Â÷ KSTH Ãá°èÇмú´ëȸÁÖÃÖ±â°ü : Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ
´ã´çÀÚ : ±èÁø¾Æ
¿¬¶ôó : 042-484-2426
À̸ÞÀÏ :
ksth@thrombo.or.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, Á¤½Å°Ç°ÀÇÇаú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, ¼ºÇü¿Ü°ú, À̺ñÀÎÈÄ°ú, ¿µ»óÀÇÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, ÀçÈ°ÀÇÇаú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаúÀÇ»çÇÐ, ¿¹¹æÀÇÇÐ, »ý¸®ÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ÀÇ·á»çȸÇÐ, ÀÇ·áÀ±¸®ÇÐ, ÀÇ·á»çȸ½É¸®ÇÐ, ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ç, ÀÇÇб³À°, ÀÇ·áÁ¤Ã¥, ÀÇ·á°æ¿µ, ±âŸ
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 40,000¿ø
ºñ°í »çÀüµî·Ïºñ 3¸¸¿ø, Àü°øÀÇ ¹× ±âŸ 1¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-24 ´ë°ÀÇ½Ç 09:30~09:50 ´ë±Ô¸ð Àα¸µ¥ÀÌÅÍ º£À̽º·Î º» Çѱ¹ÀÎ ½É¹æ¼¼µ¿°ú NOAC »ç¿ëÀÇ Æ¯¼º À̼ҷÉ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-24 ´ë°ÀÇ½Ç 09:50~10:10 2018 ´ëÇѺÎÁ¤¸Æ ÇÐȸ ºñÆǸ·¼º ½É¹æ¼¼µ¿ ȯÀÚÀÇ ³úÁ¹Áß ¿¹¹æ Áöħ Á¤º¸¿µ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-24 ´ë°ÀÇ½Ç 10:10~10:30 ½ÉÀå ³» Ç÷Àü Çü¼ºÀº Ç÷°ü ³» Ç÷Àü Çü¼º°ú ¾î¶»°Ô ±¸º°µÇ´Â°¡? Journey to the beyond NOACs ±èÄ¡°æ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 05-24 ´ë°ÀÇ½Ç 10:30~11:00 ¡°East Asian Paradox¡± and update of recent evidences ¹Ú°æ¿ì(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-24 ´ë°ÀÇ½Ç 11:00~11:30 The role of erythrocyte in arterial thrombosis À̺´±Ç(¿¬¼¼ÀÇ´ë)
ÈÞ½Ä 05-24 11:30~11:50 break ()
±³À°½Ã°£ 05-24 ´ë°ÀÇ½Ç 11:50~12:10 What¡¯s the optimal antiplatelet strategies in PAD? °í¿µ±¹(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-24 ´ë°ÀÇ½Ç 12:10~12:30 What¡¯s the role of NOAC in PAD? ¹Ú»óÈ£(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 05-24 ´ë°ÀÇ½Ç 12:30~12:50 Current best interventional practice for the treatment of acute VTE º¯½ÂÀç(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 05-24 ´ë°ÀÇ½Ç 12:50~13:00 Unmet needs and management strategies on DAPT initiation for ACS patients ±èÇö±¹(Á¶¼±ÀÇ´ë)
±³À°½Ã°£ 05-24 ´ë°ÀÇ½Ç 13:00~13:10 New treatment option for SGLT2 inhibitor in patients with T2DM ½ÉµÎ¼±(Àü³²ÀÇ´ë)
½Ä»ç 05-24 13:10~14:00 Á¡½É½Ä»ç ()
±³À°½Ã°£ 05-24 ´ë°ÀÇ½Ç 14:00~15:00 Poster Oral presentation ¾È¿µ±Ù(Àü³²ÀÇ´ë)
±³À°½Ã°£ 05-24 ´ë°ÀÇ½Ç 15:00~15:30 Patient and anticoagulation dose selection for extended treatment in VTE ³ª»óÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-24 ´ë°ÀÇ½Ç 15:30~16:00 Balloon pulmonary angioplasty in CTEPH management °µµÀ±(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05-24 ´ë°ÀÇ½Ç 16:00~16:20 Practical guide for management of splanchnic vein thrombosis ÀÌÁöÇö(µ¿¾ÆÀÇ´ë)
±³À°½Ã°£ 05-24 ´ë°ÀÇ½Ç 16:20~16:40 What is the standard to extend the anticoagulation duration in patient with cancer associated thrombosis? ÀÓÈ£¿µ(ÀüºÏÀÇ´ë)
±³À°½Ã°£ 05-24 ´ë°ÀÇ½Ç 16:40~17:00 Is it possible to use DOACs in patients with end-stage renal disease on hemodialysis? ȲÇå±Ô(¼øõÇâÀÇ´ë)
±âŸ 05-24 ´ë°ÀÇ½Ç 17:00~17:20 Çмú»ó ¹ßÇ¥ ¹× ½Ã»ó ()